Hybio Pharmaceutical Co., Ltd.
300199
Helyezés a részvények között
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Részvényárfolyam
$3.69
Piaci kapitalizáció
$3.11B
Változás (1 nap)
-7.75%
Változás (1 év)
21.56%
Ország
CN
Kereskedés Hybio Pharmaceutical Co., Ltd. (300199)
Kategória
Healthcare
Hybio Pharmaceutical Co., Ltd. (300199) nyeresége
Nyereség ekkor: Jun 2026 TTM: $23.66M
Hybio Pharmaceutical Co., Ltd. legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi nyeresége $23.66M. 2024 évben a vállalat $-22.25M nyereséget ért el, növekedés a 2023 év nyereségéhez, amely $-72.20M volt. Az ezen az oldalon megjelenített nyereség a kamatok és adók előtti eredmény, azaz EBIT.
Hybio Pharmaceutical Co., Ltd. nyereségtörténete 2007 és 2026 között
Nyereség az év végén
| Év | Nyereség | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $23.66M | 157.76% |
| 2025 | $9.18M | -141.26% |
| 2024 | $-22.25M | -69.18% |
| 2023 | $-72.20M | 33.59% |
| 2022 | $-54.05M | -1,119.96% |
| 2021 | $5.30M | -105.88% |
| 2020 | $-90.05M | -29.65% |
| 2019 | $-128.00M | 163.83% |
| 2018 | $-48.52M | -190.05% |
| 2017 | $53.88M | 20.99% |
| 2016 | $44.53M | -14.53% |
| 2015 | $52.11M | 73.20% |
| 2014 | $30.08M | 23.42% |
| 2013 | $24.38M | 44.61% |
| 2012 | $16.86M | 13.35% |
| 2011 | $14.87M | 79.07% |
| 2010 | $8.30M | 48.60% |
| 2009 | $5.59M | 70.78% |
| 2008 | $3.27M | 57.76% |
| 2007 | $2.07M | 0.00% |
Hasonló cégek vagy versenytársak nyeresége
| Vállalat | Nyereség | Nyereségkülönbség | Ország |
|---|---|---|---|
| $3.62B | 15,188.96% |
DE
|
|
| $3.40B | 14,289.34% |
DE
|
|
| $1.72B | 7,183.94% |
JP
|
|
| $930.30M | 3,831.42% |
CH
|
|
| $1.76B | 7,356.94% |
IN
|
